FoCUS participants have identified four payer segments for precision financing: self-insured employers and related organizations; health insurance plans and managed care organizations; Medicare; and Medicaid. Download FoCUS Research Brief_2018F202-014Share the … Read More
Interview with Mark Trusheim for ADAPT SMART
Road MAPPs to therapeutic innovation One of the original thought leaders of the concept of Adaptive Pathways was the NEWDIGS initiative of MIT’s Center for Biomedical Innovation. ADAPT SMART has … Read More
Payers Open to Innovative Financing Mechanisms for High Cost Gene Therapies
In a broad survey, payers favor performance based milestone contracts and risk pools strategies to absorb the surge of high cost gene therapy products expected to enter the market over … Read More
Massachusetts to Pioneer Next Generation Healthcare Innovation Ecosystem to Better Serve Patients
NEWDIGS Initiative at MIT leads multi-stakeholder collaboration to design and pilot a sustainable, patient-centered innovation ecosystem for a target disease CAMBRIDGE, MASSACHUSETTS, 12 DECEMBER 2017— MIT’s Center for Biomedical Innovation … Read More
MIT NEWDIGS Design Lab advances work on curative treatment financing strategies
Industry leaders, patient advocates, policymakers collaborate to make groundbreaking new therapies economically sustainable CAMBRIDGE, MASSACHUSETTS—The MIT NEW Drug Development ParadIGmS (NEWDIGS) initiative, an international biomedical innovation “think and do tank” … Read More
Gigi Hirsch and Hans-Georg Eichler featured in MGH’s Proto Magazine
Phasing Out Phase 3 What if drugs were released to the public earlier, then graded on their performance in the real world? Read the article here: http://protomag.com/articles/phasing-out-phase-3
Next Wave Forum
December 12–13, 2017 at MIT Biomedical science is outpacing the system. Barriers prevent patients’ access to innovations. Are you ready to innovation how we innovate? The Next Wave in Adaptive Biomedical … Read More
Mark Trusheim featured on Bloomberg News
BLOOMBERG: Novartis’s $475,000 Cancer Breakthrough Heralds New Era of Cures There are more than 600 gene and cell therapies in clinical trials today, according to Mark Trusheim, a strategic director … Read More
MIT NEWDIGS Hosts Design Lab on Efficacy to Effectiveness (E2E) data and decision-making
Industry leaders, patient advocates, regulators, policymakers collaborate to identify strategies for better data use in healthcare innovation CAMBRIDGE, MASSACHUSETTS—The MIT NEW Drug Development ParadIGmS (NEWDIGS) initiative, an international biomedical innovation … Read More
AI and machine learning key enablers of healthcare value, expert panel says
MIT NEWDIGS Director and advisor speak at LIGHT Forum on AI in Healthcare CAMBRIDGE, MASSACHUSETTS—MIT NEW Drug Development ParadIGmS (NEWDIGS) director Dr Gigi Hirsch, and program advisor R. John Glasspool … Read More